9.13%
16.10%
31.33%
138.42%
139.04%
66.22%
86.57%
AI Spotlight on PHM
Company Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally.The company operates through three segments: Oncology, Diagnostics, and RNA interference.It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.
The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors.In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression.The company was incorporated in 1986 and is based in Madrid, Spain.
Market Data
| Last Price | 92.65 |
| Change Percentage | 9.13% |
| Open | 85 |
| Previous Close | 84.9 |
| Market Cap ( Millions) | 1622 |
| Volume | 158850 |
| Year High | 92.8 |
| Year Low | 26.16 |
| M A 50 | 78.27 |
| M A 200 | 52.45 |
Financial Ratios
| FCF Yield | -1.09% |
| Dividend Yield | 0.70% |
| ROE | 0.33% |
| Debt / Equity | 21.12% |
| Net Debt / EBIDTA | 253.17% |
| Price To Book | 8.97 |
| Price Earnings Ratio | 2627.55 |
| Price To FCF | -91.81 |
| Price To sales | 9.71 |
| EV / EBITDA | 1119.64 |
News
- Jan -23 - 3 Growth Stocks With Insider Ownership Expecting Up To 71% Earnings Growth
- Jan -13 - High Growth Tech Stocks To Watch In January 2025
- Jan -06 - 3 Stocks Estimated To Be Up To 48% Below Intrinsic Value
- Dec -25 - Insider-Led Growth Stocks To Watch In December 2024
- Dec -13 - High Growth Tech Stocks With Promising Potential
- Dec -04 - 3 Stocks Estimated To Be Trading At Up To 49.2% Below Intrinsic Value
- Nov -26 - 3 Insider-Favored Growth Companies To Watch
- Nov -14 - High Growth Tech Stocks To Watch In The Current Market
- Nov -06 - Pharma Mar SA Reports Strong Revenue Growth in 2024
- Oct -21 - 3 Growth Stocks With High Insider Ownership And Earnings Up To 55%
- Oct -16 - High Growth Tech Highlights Three Promising Stocks
- Oct -15 - PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Sep -20 - September 2024's Top Growth Picks With High Insider Ownership
- Aug -21 - 3 Growth Stocks With Insider Ownership Up To 14%
- Jul -10 - 3 Growth Companies With High Insider Ownership And Up To 23% Revenue Growth
- Jun -06 - Exploring Three Growth Companies Where Insiders Hold The Reins
- Jun -04 - PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oncology
Expected Growth : 10.9 %
What the company do ?
Oncology from Pharma Mar, S.A. refers to the company's research and development of anti-tumor compounds, particularly Yondelis, a chemotherapy medication for soft tissue sarcoma and ovarian cancer.
Why we expect these perspectives ?
Strong demand for Oncology treatments, increasing cancer prevalence, and innovative pipeline of Pharma Mar's Yondelis and lurbinectedin drive 10.9% growth. Expanding indications, geographic reach, and strategic partnerships further fuel growth. Additionally, investments in R&D and regulatory approvals for new products contribute to the segment's rapid expansion.
Segment n°2 -> Diagnostics
Expected Growth : 8.32 %
What the company do ?
Diagnostics from Pharma Mar, S.A. is a leading provider of diagnostic products for cancer and genetic disorders, offering a range of innovative solutions for healthcare professionals.
Why we expect these perspectives ?
Pharma Mar's diagnostics segment growth of 8.32% is driven by increasing demand for personalized medicine, advancements in genomics and proteomics, and rising adoption of precision medicine. Additionally, growing incidence of chronic diseases, aging population, and expansion into new markets contribute to the segment's growth.
Segment n°3 -> RNAi
Expected Growth : 10.5 %
What the company do ?
RNAi from Pharma Mar, S.A. is a gene silencing technology that uses small RNA molecules to selectively inhibit gene expression, treating cancer and other diseases.
Why we expect these perspectives ?
RNAi from Pharma Mar, S.A. growth driven by increasing adoption in oncology and rare genetic disorders, strong pipeline of novel RNAi therapeutics, and strategic partnerships for commercialization. Additionally, growing demand for targeted therapies and increasing investment in RNAi research contribute to the 10.5% growth rate.
Pharma Mar, S.A. Products
| Product Range | What is it ? |
|---|---|
| Yondelis | Yondelis is a chemotherapy medication used to treat soft tissue sarcoma and ovarian cancer. |
| Zepzelca | Zepzelca is a chemotherapy medication used to treat metastatic soft tissue sarcoma and liposarcoma. |
| Aplidin | Aplidin is a chemotherapy medication used to treat multiple myeloma. |
| Trabectedin | Trabectedin is a chemotherapy medication used to treat soft tissue sarcoma and ovarian cancer. |
Pharma Mar, S.A.'s Porter Forces
Threat Of Substitutes
Pharma Mar, S.A. faces moderate threat from substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.
Bargaining Power Of Customers
Pharma Mar, S.A. has a diverse customer base, and individual customers do not have significant bargaining power.
Bargaining Power Of Suppliers
Pharma Mar, S.A. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power.
Threat Of New Entrants
The pharmaceutical industry is highly competitive, and new entrants can easily disrupt the market with innovative products and technologies.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 17.68% |
| Debt Cost | 3.95% |
| Equity Weight | 82.32% |
| Equity Cost | 3.51% |
| WACC | 3.59% |
| Leverage | 21.47% |
Pharma Mar, S.A. : Quality Control
Pharma Mar, S.A. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LVTX | LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the … |
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| PRQR | ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| ATAI | Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
ProQR Therapeutics
A-Score
1-Year Total Return ->
🥉
Gubra
A-Score
1-Year Total Return ->
4
LAVA Therapeutics
A-Score
1-Year Total Return ->
5
BioArctic
A-Score
1-Year Total Return ->
6
